This PLGA matrix-based whole-cell cancer vaccine successfully elicited antigen-specific CD8+ T cells and improved both prophylactic and therapeutic anti-tumor efficacy, compared with a conventional whole-cell vaccine GVAX, composed of irradiated, GM-CSF-secreting tumor cells. This evidence concerns the gene CD8A and cancer.